Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New players in old amyloid precursor protein-processing pathways.

Steffen Rossner1

  • 1Department of Neurochemistry, Paul Flechsig Institute for Brain Research, University of Leipzig, Janhnallee 59, 04109 Leipzig, Germany. rossn@medizin.uni-leipzig.de

International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience
|October 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aberrant FICD-mediated AMPylation drives α-Synuclein pathology and overall protein dyshomeostasis in dopaminergic neurons in Parkinson's disease.

bioRxiv : the preprint server for biology·2026
Same author

Local arrangement of microfibrillar-associated protein 5 with neurovascular and extracellular components in non- and ischemia-affected brain regions of mice.

Frontiers in neuroscience·2025
Same author

Monomers, Dimers, and Oligomers of Pyroglutamate-Modified α-Synuclein Fragments Exhibit Distinct Biophysical Characteristics.

ACS chemical neuroscience·2025
Same author

The prolyl oligopeptidase and α-synuclein connection revisited.

Biochimie·2025
Same author

Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer's disease, dementia with Lewy bodies and vascular dementia.

Acta neuropathologica·2024
Same author

Dipeptidyl peptidase 4 deficiency improves survival after focal cerebral ischemia in mice and ameliorates microglia activation and specific inflammatory markers.

Neurobiology of disease·2024

Munc13-1 modulates amyloid precursor protein (APP) processing independently of protein kinase Cs (PKCs). Targeting Munc13-1 may offer a novel therapeutic strategy for Alzheimer's disease (AD) by shifting APP metabolism away from amyloidogenic pathways.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Amyloid precursor protein (APP) processing generates beta-amyloid peptides, key components of Alzheimer's disease (AD) senile plaques.
  • Beta-site APP-cleaving enzyme 1 (BACE1) activity is crucial for beta-amyloid generation and is elevated in AD brains.
  • Reactive astrocytes may also express BACE1, suggesting a role in AD pathogenesis.

Purpose of the Study:

  • To investigate the role of Munc13-1, a diacylglycerol (DAG)/phorbol ester (PE) target, in modulating APP processing.
  • To determine if Munc13-1 acts in parallel or through protein kinase Cs (PKCs) in regulating APP metabolism.

Main Methods:

  • Utilized Munc13-1 knock-out mice.
  • Employed human neuroblastoma cells transfected with wild-type and mutant Munc13-1 constructs.

Related Experiment Videos

Main Results:

  • Demonstrated that Munc13-1 modulates APP metabolism independently of PKCs.
  • Munc13-1 acts in a parallel pathway to PKCs in regulating APP processing.

Conclusions:

  • Munc13-1 represents an alternative target to PKCs for modulating APP processing.
  • Agonists targeting Munc13-1's C1-domain or mimicking RIM1 function could shift APP processing to the non-amyloidogenic pathway, offering potential AD therapeutics.